Alvotech Sets Sights On Stelara Submission By Close Of 2022

Company In Strong Position To Capitalize On Ustekinumab Opportunity

 
• By Dean Rudge

Tipped to bring in revenues from its proposed Stelara biosimilar of $600m in 2027, Alvotech has confirmed plans for a potentially landmark filing with major regulators by the end of the year.

Andrii Yalanskyi/Alamy Stock Photo
With positive data in hand, filings are set to follow • Source: Shutterstock (Andrii Yalanskyi / Alamy Stock P/Alamy Stock Photo)

More from Biosimilars

More from Products